Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome, Human | 8 | 2023 | 24 | 3.870 |
Why?
|
| Genome-Wide Association Study | 12 | 2023 | 100 | 3.740 |
Why?
|
| Genetic Variation | 11 | 2023 | 169 | 2.480 |
Why?
|
| Genomics | 10 | 2023 | 106 | 2.360 |
Why?
|
| Polymorphism, Single Nucleotide | 14 | 2023 | 190 | 1.760 |
Why?
|
| Human Migration | 2 | 2021 | 8 | 1.480 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2023 | 168 | 1.340 |
Why?
|
| Genetics, Population | 6 | 2021 | 50 | 1.200 |
Why?
|
| Memory, Episodic | 1 | 2023 | 3 | 0.870 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2022 | 158 | 0.830 |
Why?
|
| Humans | 32 | 2023 | 14077 | 0.820 |
Why?
|
| HLA Antigens | 1 | 2022 | 50 | 0.820 |
Why?
|
| DNA, Ancient | 1 | 2021 | 3 | 0.760 |
Why?
|
| Health | 1 | 2020 | 11 | 0.730 |
Why?
|
| Adaptation, Biological | 1 | 2018 | 5 | 0.630 |
Why?
|
| Africa | 6 | 2023 | 360 | 0.600 |
Why?
|
| Whole Genome Sequencing | 4 | 2022 | 40 | 0.570 |
Why?
|
| Language | 3 | 2021 | 13 | 0.560 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 2 | 2022 | 7 | 0.410 |
Why?
|
| History, Ancient | 2 | 2021 | 6 | 0.370 |
Why?
|
| Haplotypes | 3 | 2021 | 119 | 0.370 |
Why?
|
| Gene Flow | 2 | 2021 | 9 | 0.370 |
Why?
|
| South Africa | 10 | 2023 | 7312 | 0.340 |
Why?
|
| Phenotype | 4 | 2023 | 144 | 0.340 |
Why?
|
| Selection, Genetic | 3 | 2020 | 31 | 0.330 |
Why?
|
| Genetics, Medical | 3 | 2020 | 21 | 0.330 |
Why?
|
| Datasets as Topic | 2 | 2020 | 15 | 0.320 |
Why?
|
| Male | 11 | 2022 | 6489 | 0.320 |
Why?
|
| Cardiovascular Diseases | 3 | 2022 | 235 | 0.310 |
Why?
|
| Africa South of the Sahara | 4 | 2022 | 328 | 0.300 |
Why?
|
| Polymorphism, Genetic | 2 | 2018 | 96 | 0.280 |
Why?
|
| Evolution, Molecular | 2 | 2018 | 60 | 0.270 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 1377 | 0.250 |
Why?
|
| Pharmacogenetics | 2 | 2022 | 27 | 0.240 |
Why?
|
| Female | 10 | 2023 | 8751 | 0.220 |
Why?
|
| Esophageal Neoplasms | 1 | 2023 | 26 | 0.220 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 30 | 0.220 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2023 | 32 | 0.220 |
Why?
|
| Lim Kinases | 1 | 2022 | 4 | 0.210 |
Why?
|
| HLA-DRB1 Chains | 1 | 2022 | 17 | 0.210 |
Why?
|
| Benchmarking | 1 | 2022 | 10 | 0.210 |
Why?
|
| Cognition | 1 | 2023 | 75 | 0.210 |
Why?
|
| Body Mass Index | 2 | 2021 | 312 | 0.200 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 5 | 0.190 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2021 | 7 | 0.190 |
Why?
|
| Chloroquine | 1 | 2021 | 10 | 0.190 |
Why?
|
| Databases, Genetic | 2 | 2021 | 20 | 0.190 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2022 | 104 | 0.190 |
Why?
|
| Africa, Southern | 1 | 2021 | 89 | 0.190 |
Why?
|
| DNA-Binding Proteins | 2 | 2018 | 20 | 0.190 |
Why?
|
| Metabolism | 1 | 2020 | 3 | 0.180 |
Why?
|
| Immunity | 1 | 2020 | 10 | 0.180 |
Why?
|
| DNA Repair | 1 | 2020 | 11 | 0.180 |
Why?
|
| Cholesterol, LDL | 1 | 2022 | 137 | 0.180 |
Why?
|
| Demography | 1 | 2021 | 105 | 0.180 |
Why?
|
| Atherosclerosis | 1 | 2022 | 97 | 0.180 |
Why?
|
| Blood Pressure | 2 | 2023 | 312 | 0.170 |
Why?
|
| Pharmacogenomic Variants | 1 | 2019 | 2 | 0.170 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 47 | 0.170 |
Why?
|
| Hypertension | 1 | 2023 | 397 | 0.160 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 180 | 0.160 |
Why?
|
| Genetics | 1 | 2018 | 3 | 0.160 |
Why?
|
| Biological Evolution | 1 | 2018 | 9 | 0.160 |
Why?
|
| Genetic Techniques | 1 | 2018 | 9 | 0.160 |
Why?
|
| Alleles | 2 | 2021 | 134 | 0.160 |
Why?
|
| Gene-Environment Interaction | 1 | 2018 | 11 | 0.150 |
Why?
|
| Healthy Volunteers | 1 | 2017 | 18 | 0.150 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 34 | 0.150 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 20 | 0.150 |
Why?
|
| Metabolic Diseases | 1 | 2018 | 30 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2017 | 168 | 0.140 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2017 | 1 | 0.140 |
Why?
|
| Population | 1 | 2016 | 5 | 0.140 |
Why?
|
| Body Composition | 1 | 2018 | 150 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 36 | 0.140 |
Why?
|
| Mutation | 1 | 2017 | 299 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2018 | 325 | 0.130 |
Why?
|
| Gene Frequency | 3 | 2021 | 117 | 0.120 |
Why?
|
| Databases, Nucleic Acid | 1 | 2014 | 3 | 0.120 |
Why?
|
| Recombination, Genetic | 1 | 2014 | 27 | 0.120 |
Why?
|
| Computational Biology | 1 | 2014 | 43 | 0.110 |
Why?
|
| Lipids | 2 | 2022 | 81 | 0.100 |
Why?
|
| Middle Aged | 4 | 2022 | 3425 | 0.100 |
Why?
|
| Disease | 1 | 2011 | 12 | 0.100 |
Why?
|
| Adult | 5 | 2022 | 5664 | 0.100 |
Why?
|
| Genotype | 3 | 2018 | 430 | 0.090 |
Why?
|
| Sex Factors | 2 | 2022 | 224 | 0.090 |
Why?
|
| Chromosome Mapping | 2 | 2021 | 20 | 0.090 |
Why?
|
| Risk Factors | 3 | 2021 | 1431 | 0.080 |
Why?
|
| Geography | 2 | 2021 | 60 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 449 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2019 | 939 | 0.060 |
Why?
|
| Aged | 2 | 2021 | 1650 | 0.060 |
Why?
|
| Proteomics | 1 | 2023 | 13 | 0.060 |
Why?
|
| Uganda | 1 | 2023 | 194 | 0.050 |
Why?
|
| Genetic Pleiotropy | 1 | 2022 | 2 | 0.050 |
Why?
|
| United Kingdom | 1 | 2022 | 32 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2022 | 43 | 0.050 |
Why?
|
| Chromatin | 1 | 2022 | 2 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2023 | 217 | 0.050 |
Why?
|
| Gastrointestinal Hormones | 1 | 2022 | 4 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor, Endocrine-Gland-Derived | 1 | 2022 | 4 | 0.050 |
Why?
|
| Sorting Nexins | 1 | 2022 | 4 | 0.050 |
Why?
|
| Ribonucleoproteins | 1 | 2022 | 6 | 0.050 |
Why?
|
| Histones | 1 | 2022 | 7 | 0.050 |
Why?
|
| Genome | 1 | 2022 | 9 | 0.050 |
Why?
|
| Autoantigens | 1 | 2022 | 10 | 0.050 |
Why?
|
| Smoking | 1 | 2022 | 99 | 0.050 |
Why?
|
| Population Groups | 1 | 2021 | 9 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2023 | 464 | 0.050 |
Why?
|
| Multifactorial Inheritance | 1 | 2021 | 7 | 0.050 |
Why?
|
| Linkage Disequilibrium | 1 | 2021 | 40 | 0.050 |
Why?
|
| Linguistics | 1 | 2021 | 5 | 0.050 |
Why?
|
| Chromosomes, Human, Y | 1 | 2021 | 9 | 0.050 |
Why?
|
| Mutation, Missense | 1 | 2021 | 65 | 0.050 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2021 | 7 | 0.050 |
Why?
|
| Brazil | 1 | 2021 | 43 | 0.050 |
Why?
|
| Adolescent | 2 | 2018 | 2858 | 0.050 |
Why?
|
| Phylogeny | 1 | 2021 | 231 | 0.040 |
Why?
|
| Database Management Systems | 1 | 2017 | 5 | 0.040 |
Why?
|
| Nigeria | 1 | 2017 | 40 | 0.040 |
Why?
|
| Organic Cation Transporter 2 | 1 | 2017 | 1 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2017 | 9 | 0.040 |
Why?
|
| Human Genome Project | 1 | 2016 | 6 | 0.040 |
Why?
|
| Bias | 1 | 2016 | 12 | 0.040 |
Why?
|
| India | 1 | 2016 | 60 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 364 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2021 | 1675 | 0.030 |
Why?
|
| Europe | 1 | 2014 | 53 | 0.030 |
Why?
|
| Child | 1 | 2021 | 2180 | 0.030 |
Why?
|
| Asia | 1 | 2014 | 70 | 0.030 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2014 | 4 | 0.030 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2014 | 4 | 0.030 |
Why?
|
| Immunoglobulin J Recombination Signal Sequence-Binding Protein | 1 | 2014 | 4 | 0.030 |
Why?
|
| Receptors, Interleukin-1 Type I | 1 | 2014 | 4 | 0.030 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2014 | 4 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2014 | 7 | 0.030 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2014 | 8 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 14 | 0.030 |
Why?
|
| Developing Countries | 1 | 2017 | 385 | 0.030 |
Why?
|
| Young Adult | 1 | 2021 | 2357 | 0.030 |
Why?
|